The Drug-Induced Respiratory Disease Website

Osimertinib

Subclinical pulmonary infiltrates/ILD

(Fr. atteinte infraclinique). Interstitial or alveolar opacities detected incidentally on HRCT or if the BAL shows increased lymphocytes, neutrophils or eosinophils. PFTs typically yield normal results. See also under Iv

Publications

Lu H, Dowell J

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In vivo (Athens, Greece) 2020 Jan-Feb;34;315-319 — 2020 Jan-Feb — 315-319

Lee H, Lee HY, Sun JM, Lee SH, Kim Y, Park SE, Ahn JS, Park K, Ahn MJ

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 08;13;1106-1112 — 2018 08 — 1106-1112

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

Diagnosing DIRD

Identify causative drugs

LATEST CHANGELOG

No activity has been recorded yet.

View full changelog